Key Points
- Ra Capital Management, L.P. (a director) purchased 3,690,000 shares of Spyglass Pharma at $16.00 each on Feb. 9, totaling $59,040,000 and raising its holdings to 5,966,439 shares (a 162.10% increase) valued at about $95.46M.
- Spyglass Pharma (NASDAQ:SGP) shares opened at $27.69 with a 52‑week range of $20.16–$32.44, and Wall Street Zen recently upgraded the stock to a "hold" rating.
Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) Director Ra Capital Management, L.P. bought 3,690,000 shares of the company's stock in a transaction dated Monday, February 9th. The stock was bought at an average cost of $16.00 per share, with a total value of $59,040,000.00. Following the completion of the acquisition, the director owned 5,966,439 shares in the company, valued at $95,463,024. This represents a 162.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Spyglass Pharma Price Performance
Shares of NASDAQ:SGP opened at $27.69 on Wednesday. Spyglass Pharma, Inc. has a fifty-two week low of $20.16 and a fifty-two week high of $32.44.
Analyst Ratings Changes
Separately, Wall Street Zen raised shares of Spyglass Pharma to a "hold" rating in a report on Tuesday.
Read Our Latest Report on Spyglass Pharma
About Spyglass Pharma
(
Get Free Report)
We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
